Segment Information |
12 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Segment Reporting [Abstract] | |
| Segment Information | Segment Information We operate as one operating segment, which includes all activities related to the discovery and development of our clinical and preclinical product candidates, for the purposes of assessing performance, making operating decisions, and allocating our resources. Our chief operating decision maker (CODM) is our President and Chief Executive Officer. The CODM regularly reviews total operating expenses, disaggregated into research and development expense and general and administrative expense, against budget and prior periods. The CODM also monitors cash, cash equivalents, and marketable securities and internal cash forecasts to assess the sufficiency of cash resources to support our research and development activities. The categories of significant expenses regularly provided to the CODM are reflected in our consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on our consolidated balance sheets as total consolidated assets, and segment loss is reflected as net loss in our consolidated statements of operations and comprehensive loss.
|